Stock Analiz

Core Laboratories Inc. CLB

Oilfield Services/Equipment · IPO 2023 · data as of November 13, 2026

$9.11Market cap $417M
Open the interactive analysis →

Core Laboratories Inc. (CLB) is a energy company listed in the US with a market value of about $417M. In the twelve months to September 30, 2026 it had revenue of $517M and net income of $16M, a net margin of 3.0%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a P/E of 26.8, a price to free cash flow of 40.3, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 57% below the current price.

About Core Laboratories

Core Laboratories is listed in the US and classified in oilfield services/equipment, IPO year 2023. Revenue went from $470M in 2021 to $527M in 2025, growth of about 2.9% a year. It was profitable in 5 of the last 5 years in our data.

Score: 1.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health3/5
Shareholder returns3/5

Checks passed

  • 3-year free cash flow growth above 10% a year
  • Profitable 5 years in a row
  • Positive free cash flow
  • Interest covered more than 5 times
  • Liabilities below 60% of assets
  • Pays a dividend
  • Dividend 3 years in a row
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)26.8
Forward P/E14.1
P/FCF40.3
P/S0.8
P/B1.5
EV/EBITDA10.4
PEG—
Dividend yield0.44%
FCF yield2.5%
Shareholder yield3.4%
Intrinsic value vs. price−57%

Growth and quality

Revenue growth (1 yr)0.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)20.5%
Net margin (5-yr avg.)5.4%
ROIC (5-yr avg.)10.3%
Profitable years (of last 10)5
Years paying a dividend5

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$517M$527M$524M$510M$490M$470M
Net income$16M$30M$31M$37M$19M$20M
Free cash flow$10M$26M$44M$14M$15M$23M
EPS (diluted)$0.34$0.63$0.66$0.77$0.42$0.42
Net margin3.0%5.6%6.0%7.2%4.0%4.2%
ROIC—8.6%9.5%11.1%6.7%15.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $15.00, 65% above the current price; targets range from $11.00 to $21.00; the consensus rating is “none”; expected EPS is $0.51 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Core Laboratories’s P/E ratio?

About 26.8, based on the last twelve months of diluted earnings per share (forward P/E about 14.1).

Is Core Laboratories stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 57% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Core Laboratories pay a dividend?

Yes. The dividend yield is about 0.44%, and it has paid dividends for 5 years in our data.

Is Core Laboratories a good stock to buy?

We do not give buy or sell advice. Core Laboratories scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.